Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hematopoiesis under telomere attrition at the single-cell resolution.
Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, Adema V, Ganan-Gomez I, Groarke EM, Gutierrez-Rodrigues F, Chen S, Lockyer P, Schneider S, Bueso-Ramos C, Montalban-Bravo G, Class CA, Soltysiak KA, Pellegrini M, Sahin E, Bertuch AA, DiNardo CD, Garcia-Manero G, Young NS, Dwyer K, Colla S. Thongon N, et al. Among authors: adema v. Nat Commun. 2021 Nov 25;12(1):6850. doi: 10.1038/s41467-021-27206-7. Nat Commun. 2021. PMID: 34824242 Free PMC article.
EZH2 Inhibitors: The Unpacking Revolution.
Adema V, Colla S. Adema V, et al. Cancer Res. 2022 Feb 1;82(3):359-361. doi: 10.1158/0008-5472.CAN-21-4311. Cancer Res. 2022. PMID: 35110396
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Ganan-Gomez I, et al. Among authors: adema v. Nat Med. 2022 Mar;28(3):557-567. doi: 10.1038/s41591-022-01696-4. Epub 2022 Mar 3. Nat Med. 2022. PMID: 35241842 Free PMC article.
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Ganan-Gomez I, et al. Among authors: adema v. Nat Med. 2022 May;28(5):1097. doi: 10.1038/s41591-022-01827-x. Nat Med. 2022. PMID: 35484266 Free PMC article. No abstract available.
Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts.
Adema V, Ma F, Kanagal-Shamanna R, Thongon N, Montalban-Bravo G, Yang H, Peslak SA, Wang F, Acha P, Sole F, Lockyer P, Cassari M, Maciejewski JP, Visconte V, Gañán-Gómez I, Song Y, Bueso-Ramos C, Pellegrini M, Tan TM, Bejar R, Carew JS, Halene S, Santini V, Al-Atrash G, Clise-Dwyer K, Garcia-Manero G, Blobel GA, Colla S. Adema V, et al. Blood Cancer Discov. 2022 Nov 2;3(6):554-567. doi: 10.1158/2643-3230.BCD-21-0220. Blood Cancer Discov. 2022. PMID: 35926182 Free PMC article.
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes.
Nazha A, Komrokji R, Meggendorfer M, Jia X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK, Mukherjee S, Al Ali N, Walter W, Hutter S, Padron E, Sallman D, Kuzmanovic T, Kerr C, Adema V, Steensma DP, Dezern A, Roboz G, Garcia-Manero G, Erba H, Haferlach C, Maciejewski JP, Haferlach T, Sekeres MA. Nazha A, et al. Among authors: adema v. J Clin Oncol. 2021 Nov 20;39(33):3737-3746. doi: 10.1200/JCO.20.02810. Epub 2021 Aug 18. J Clin Oncol. 2021. PMID: 34406850 Free PMC article.
What lies beyond del(5q) in myelodysplastic syndrome?
Adema V, Bejar R. Adema V, et al. Haematologica. 2013 Dec;98(12):1819-21. doi: 10.3324/haematol.2013.094912. Haematologica. 2013. PMID: 24323981 Free PMC article. No abstract available.
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.
Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL. Schneider RK, et al. Among authors: adema v. Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18. Cancer Cell. 2014. PMID: 25242043 Free PMC article.
Inspecting Targeted Deep Sequencing of Whole Genome Amplified DNA Versus Fresh DNA for Somatic Mutation Detection: A Genetic Study in Myelodysplastic Syndrome Patients.
Palomo L, Fuster-Tormo F, Alvira D, Ademà V, Armengol MP, Gómez-Marzo P, de Haro N, Mallo M, Xicoy B, Zamora L, Solé F. Palomo L, et al. Among authors: adema v. Biopreserv Biobank. 2017 Aug;15(4):360-365. doi: 10.1089/bio.2016.0094. Epub 2017 Jun 6. Biopreserv Biobank. 2017. PMID: 28586236
52 results